Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study.

Area of Science:

• Pharmacology
• Addiction Medicine
• Cannabinoid Research

Background:

• Cannabis dependence poses a significant public health challenge.
• Existing pharmacotherapies for cannabis dependence are limited.
• Nabilone, a synthetic cannabinoid agonist, is explored as a potential treatment.

Purpose of the Study:

• To evaluate the safety and tolerability of nabilone in adults with cannabis dependence.
• To assess the preliminary efficacy of nabilone in reducing cannabis use.
• To investigate nabilone's impact on cannabis craving and anxiety.

Main Methods:

• A randomized, placebo-controlled trial involving 18 adults with DSM-IV cannabis dependence.
• Participants received either 2 mg/day of nabilone or placebo for 10 weeks, alongside medication management.
• Outcomes included self-reported cannabis use, urine cannabinoid tests, craving, and anxiety assessments.

Main Results:

• Nabilone was found to be safe and well-tolerated, with all adverse events being mild to moderate.
• No serious adverse events were reported for nabilone or placebo.
• While self-reported cannabis use decreased in both groups, the reduction was not statistically significant, and no difference was observed between nabilone and placebo.

Conclusions:

• Nabilone demonstrates a favorable safety and tolerability profile for treating cannabis dependence.
• Higher doses of nabilone may warrant investigation in future trials to determine efficacy.
• Nabilone remains a potential candidate for further pharmacotherapy research in cannabis dependence.